RxDoctor Payments Data

Claudette Gbemudu-Jatto, MD

Internal Medicine · Harrisburg, PANPI 1376505040

Payments from drug & device makers

$812in general payments, 2019–2025

Across 41 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$126
  • Novo Nordisk$93
  • Merz North America, Inc.$92
  • Neotract Inc.$81
  • Lilly USA, LLC$59
  • AbbVie$54
  • plus $307 from 11 others

What the payments were for

  • Food & beverage$77595%
  • Education$375%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$812 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$146,627
Medicare patients
90
Services billed
1,713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$51,606
JanuviaSitagliptin Phosphate31$45,848
EliquisApixaban31$36,833
JardianceEmpagliflozin29$36,817
JanumetSitagliptin Phos/Metformin Hcl39$36,311
FarxigaDapagliflozin Propanediol21$25,343
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$15,412
KaterziaAmlodipine Benzoate11$12,348
SynthroidLevothyroxine Sodium49$2,792
Rosuvastatin Calcium105$2,775
Atorvastatin Calcium117$2,550
Icosapent Ethyl13$2,512
Valsartan76$2,469
Metoprolol Succinate103$2,226
Clonidine14$2,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$93$51,60641 claims
PfizerEliquis$29$36,83331 claims
AstraZenecaFarxiga$126$25,34321 claims
AbbVieSynthroid$54$2,79249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →